Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 12:14 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 711 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopy Clear all
Completed Phase 2 Interventional Results available

A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

NCT03921411
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nemolizumab
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Fountain Valley, California • Fremont, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Not applicable Interventional Results available

Acupressure in Pruritus for Atopic Dermatitis

NCT01074164
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Standard-of-care treatment for AD, Accu-patch pellet
Other · Device
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 5, 2015 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 1Phase 2 Interventional

Beginning Assessment of Cutaneous Treatment Efficacy of Roseomonas in Atopic Dermatitis

NCT03018275
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Roseomonas mucosa
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 99 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 27, 2019 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

NCT00316602
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
IMVAMUNE
Biological
Lead sponsor
Bavarian Nordic
Industry
Eligibility
18 Years to 40 Years
Enrollment
632 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
15
States / cities
Tucson, Arizona • Hot Springs, Arkansas • Garden Grove, California + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2019 · Synced Oct 28, 2026, 12:14 AM EDT
Completed No phase listed Observational

Hydration Sensor for Atopic Dermatitis

NCT03813472
View directory record Official record
Conditions
Atopic Dermatitis, Healthy Children
Interventions
Hydration Sensor
Device
Lead sponsor
Northwestern University
Other
Eligibility
Up to 18 Years
Enrollment
172 participants
Timeline
2019 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 6, 2023 · Synced Oct 28, 2026, 12:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Skin Tape Transcriptome Methods in Children

NCT04180644
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Skin tape strips
Other
Lead sponsor
National Jewish Health
Other
Eligibility
4 Years to 12 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 13, 2020 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Efficacy, Safety and Pharmacokinetics of ASB17061 Capsules in Adult Subjects With Atopic Dermatitis

NCT01756898
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
5 mg ASB17061, Placebo, 10 mg ASB17061, 20 mg ASB17061
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 65 Years
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
40
States / cities
Birmingham, Alabama • Phoenix, Arizona • Rogers, Arkansas + 35 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2021 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study Of PF-06817024 In Healthy Subjects, In Patients With Chronic Rhinosinusitis With Nasal Polyps And in Patients With Atopic Dermatitis

NCT02743871
View directory record Official record
Conditions
Healthy, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis
Interventions
PF-06817024, Placebo for PF-06817024
Biological · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
97 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
20
States / cities
Sacramento, California • New Haven, Connecticut • Shelton, Connecticut + 12 more
Source: ClinicalTrials.gov public record
Updated May 19, 2022 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 4 Interventional Results available

A Study of Crisaborole Ointment 2% in Children Aged 3-24 Months With Mild to Moderate Atopic Dermatitis

NCT03356977
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole ointment 2%
Drug
Lead sponsor
Pfizer
Industry
Eligibility
3 Months to 23 Months
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
23
States / cities
Hot Springs, Arkansas • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2019 · Synced Oct 28, 2026, 12:14 AM EDT
Suspended No phase listed Observational Accepts healthy volunteers

A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease

NCT04031469
View directory record Official record
Conditions
Gut Microbiome, Gastrointestinal Microbiome, Autism, Autism Spectrum Disorder, Autism Spectrum Disorder High-Functioning, Alzheimer Disease, Alzheimer Dementia (AD), Alzheimer Dementia, Alzheimer Disease (AD), Crohn, Crohn Colitis, Crohn Disease (CD), Crohn Disease Colon, Myalgic Encephalomyelitis, ME/CFS, Myalgic Encephalomyelitis (ME), Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, Psoriasis, Psoriasis Annularis, Psoriasis Chronic, Chronic Urinary Tract Infection, Ulcerative Colitis (Disorder), Ulcerative Colitis (UC), Ulcerative Colitis Acute, Ulcerative Colitis Chronic, Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Constipation Chronic Idiopathic, Constipation, Celiac, Celiac Disease, Celiac Sprue, Lyme Arthritis, Lyme Borreliosis, Nervous System, Lyme Disease, Chronic, Cholesterol, Cholesterol Level, High, Cancer, Colon Cancer, Amyotrophic Lateral Sclerosis (ALS), Amyotrophic Lateral Sclerosis, Rheumatoid Arthritis (RA), Rheumatoid Arthritis - Rheumatism, Chronic Fatigue Syndrome (CFS), PARKINSON DISEASE (Disorder), Parkinson Disease, Parkinson Disease (PD), Depression, Major Depressive Disorder (MDD), Depression Disorder, Depression in Adults, Anxiety, Anxiety Disorder Generalized, Obsessive Compulsive Disorder (OCD), Obsessive Compulsive Disorder OCD, Obsessive - Compulsive Disorder, Bipolar, Bipolar 1 Disorder, Bipolar Disorder (BD), Bipolar Disorder I and II, Bipolar and Related Disorders, Migraine, Migraine Disorder, Diabetes (DM), Diabetes, Lupus, Lupus Erythematosus, Epidermolysis Bullosa (EB), Mesothelioma, Mesothelioma Malignant, IBS (Irritable Bowel Syndrome), Irritable Bowel, IBS - Irritable Bowel Syndrome, Irritable Bowel Syndrome (IBS), Eczema, Eczema Atopic Dermatitis, Acne, Myasthaenia Gravis, Gout
Interventions
There is no intervention in this study
Other
Lead sponsor
ProgenaBiome
Other
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
1
States / cities
Ventura, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 28, 2026, 12:14 AM EDT
Recruiting Phase 4 Interventional

Dupixent and Narrowband UVB for Atopic Dermatitis

NCT05285839
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupixent
Drug
Lead sponsor
Psoriasis Treatment Center of Central New Jersey
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
East Windsor, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 15, 2024 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Study of Abrocitinib Compared With Dupilumab in Adults With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

NCT04345367
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Abrocitinib 200 mg, Dupilumab 300 mg
Drug · Combination Product
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
727 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
49
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fountain Valley, California + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2022 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 1 Interventional

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

NCT01259323
View directory record Official record
Conditions
Dermatitis
Interventions
REGN668
Biological
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
10
States / cities
Los Angeles, California • Riverside, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 4, 2012 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 1 Interventional

A Study of AK002 in Patients With Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, and Perennial Allergic Conjunctivitis

NCT03379311
View directory record Official record
Conditions
Atopic Keratoconjunctivitis, Vernal Keratoconjunctivitis, Perennial Allergic Conjunctivitis
Interventions
AK002
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
8
States / cities
Palo Alto, California • Edgewater, Florida • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 29, 2019 · Synced Oct 28, 2026, 12:14 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis

NCT06407934
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,541 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
82
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 1 Interventional

A First-in-Human Study of RPT193 in Healthy Volunteers and Patients With Atopic Dermatitis

NCT04271514
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
RPT193, Placebo
Drug
Lead sponsor
RAPT Therapeutics, Inc., a member of the GSK plc group of companies
Industry
Eligibility
18 Years to 65 Years
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
13
States / cities
Anniston, Alabama • Scottsdale, Arizona • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2021 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

A Test to Determine the Usefulness and Safety of a Cream Used on Babies With Dry Itchy Skin

NCT02120833
View directory record Official record
Conditions
Eczema
Interventions
EpiCeram® Skin Barrier Emulsion, Colloidal Oatmeal Cream
Device · Drug
Lead sponsor
Johnson & Johnson Consumer and Personal Products Worldwide
Industry
Eligibility
2 Months to 35 Months
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
2
States / cities
Colorado Springs, Colorado • Richardson, Texas
Source: ClinicalTrials.gov public record
Updated Jan 13, 2017 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Study of 0416 Ointment in the Treatment of Atopic Dermatitis

NCT01053247
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0416, Vehicle of 0416 test product, tacrolimus ointment 0.1%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 2 Interventional Results available

Ruxolitinib Cream in Participants With Facial and/or Neck Atopic Dermatitis Involvement

NCT05127421
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Ruxolitinib cream, Vehicle
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
12 Years to 70 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2024 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Forms of the Study Medicine Called PF 08049820 Are Taken up Into the Bloodstream in Healthy Adults

NCT07172321
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
PF-08049820 MR1, PF-08049820 MR2, PF-08049820 IR
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Oct 28, 2026, 12:14 AM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

NCT03160885
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
40
States / cities
Hot Springs, Arkansas • Encinitas, California • Fullerton, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 28, 2026, 12:14 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Improvement of Short Term Outcome of Mild to Moderate Atopic Dermatitis Using a Combination of Crisaborole and a Concomitant Topical Corticosteroid Over a 8 Week Period

NCT04008784
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Crisaborole 2% Topical Application Ointment [EUCRISA], Triamcinolone Acetonide 0.1% Ointment
Drug
Lead sponsor
Clinical Research Center of the Carolinas
Other
Eligibility
2 Years to 79 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Oct 28, 2026, 12:14 AM EDT
Recruiting No phase listed Observational

A Biorepository of Multiple Allergic Diseases (MADREP) With Longitudinal Follow-Up

NCT06732414
View directory record Official record
Conditions
Allergy, Sinus Disorders, Atopic Diseases, Asthma, Allergic Rhinitis, Atopic Dermatitis, EoE, Drug a
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 100 Years
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2045
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 28, 2026, 12:14 AM EDT